Health

JAK Inhibitor Benefits in Type 1 Diabetes Lost After Discontinuation

TribeNews
By TribeNews Add a Comment
0 Min Read
JAK Inhibitor Benefits in Type 1 Diabetes Lost After Discontinuation

MedPage Today) — The effects of the JAK inhibitor baricitinib (Olumiant) waned after treatment was stopped among patients with new-onset type 1 diabetes, 2-year data from the phase II BANDIT trial showed.
After treatment was stopped, C-peptide…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app